Table 1.
Patient and lesion characteristics
| Patients (N = 194) | Value |
|---|---|
| Age, years | 51 (23–83) |
| Menopausal status | |
| Pre | 93 (47.9) |
| Post | 101 (52.1) |
| Indication | |
| New cancer | 126 (64.9) |
| Screening/problem solving | 68 (35.1) |
| Breast density | |
| Fatty | 5 (2.6) |
| Scattered fibroglandular | 47 (24.2) |
| Heterogeneously dense | 108 (55.7) |
| Dense | 34 (17.5) |
| Background parenchymal enhancement | |
| Minimal | 58 (29.9) |
| Mild | 79 (40.7) |
| Moderate | 37 (19.1) |
| Marked | 20 (10.3) |
| Lesions per patient | |
| 1 lesion | 157 (80.9) |
| 2 lesions | 30 (15.5) |
| 3 lesions | 7 (3.6) |
| Lesions (N = 238) | |
| Largest diameter, cm | |
| < 1.0 cm | 98 (41.2) |
| 1.0–1.9 cm | 71 (29.8) |
| 2.0–3.9 cm | 38 (16.0) |
| ≥ 4.0 cm | 31 (13.0) |
| Type | |
| Mass | 135 (56.7) |
| NMLE | 99 (41.6) |
| Focus | 4 (1.7) |
| Delayed phase kinetics(most suspicious) | |
| Persistent | 6 (2.5) |
| Plateau | 34 (14.3) |
| Washout | 198 (83.2) |
| BI-RADS | |
| 4 | 218 (91.6) |
| 5 | 20 (8.4) |
| Histopathology | |
| Malignant | 95 (39.9) |
| Benign | 143 (60.1) |
| Cancer subtype (n = 90*) | |
| Invasive | 73 (81.1) |
| DCIS | 17 (18.9) |
| Benign subtype (n = 143) | |
| Fibroadenoma | 25 (17.5) |
| Fibrocystic changes | 21 (14.7) |
| Fibrosis | 14 (9.8) |
| Usual ductal hyperplasia | 12 (8.4) |
| Apocrine metaplasia | 11 (7.7) |
| Lobular neoplasia (LCIS, ALH) | 9 (6.3) |
| Papilloma | 9 (6.3) |
| Adenosis | 8 (5.6) |
| Pseudoangiomatous stromal hyperplasia | 6 (4.2) |
| Inflammation | 5 (3.5) |
| Atypical ductal hyperplasia | 4 (2.8) |
| Fibroadenomatoid change | 4 (2.8) |
| Normal breast tissue | 4 (2.8) |
| Other miscellaneous | 11 (7.7) |
Values are median (range) or no. (%)
NME non-mass enhancement, DCIS ductal carcinoma in situ, LCIS lobular carcinoma in situ, ALH atypical lobular hyperplasia
*Five malignancies did not have a cancer subtype available